Table 1.

PDX collection summary

			Clinical Subtypes (By Patient)				Tumor Source(s)					Race/Ethnicity (By Patient)
Academic Institution	Number Of Patients Represented	Number of Independent PDX Available	Estrogen Receptor Positive (Including HER2+)	HER2 Positive Only	"Triple Negative"	No Data	Primary	Pleural Effusion	Ascites	Other Metastatic Site	Not Specified	Caucasian	Hispanic	African American	Continental African	Asian	Not Reported
Baylor College of Medicine (USA)	42	51	10a	5	26b	1	37	2	2	1	0	10	21	9	0	0	2
Bellvitge Institute for Biomedical Research (SPAIN)	11	11	3c	0	8d	0	8	3	0	0	0	11	0	0	0	0	0
British Columbia Cancer Agency (CANADA)	40	40	13	6	19	1	24	4	1	10	0	0	0	0	0	0	40
Ecole Polytechnique Federale De Lausanne (CH)	2	2	1	0	1e	0	2	0	0	0	0	2	0	0	0	0	0
Institut Bergonié (FR)	4	4	3	1	0	0	4	0	0	0	0	0	0	0	0	0	4
Institut Curie (FR)	121	121	54	9	58f	0	111	2	0	8	0	0	0	0	0	0	121
The Jackson Laboratory (JAX) (USA)	29	32	7	1	20	1	22	0	0	4	3	21	1	0	0	2	5
MD Anderson Cancer Center (USA) - Meric-Bernstam	26	29	13	0	13	0	24	0	0	5	0	10	2	13	0	1	0
MD Anderson Cancer Center (USA) - Piwnica-Wormsg,h	23	26	0	0	23i	0	24	0	0	1	0	12	3	6	0	2	0
Medical Campus (USA)	25	25	11	1	12	1	20	2	2	1	0	0	0	0	0	0	25
University of Manchester Institute of Cancer Sciences (UK)	20	20	11	1	8	0	12	1	7	0	0	18	0	0	0	0	2
University of Michigan (USA)	20	21	3	3	14	0	15	5	0	1	0	6	0	4	9	0	1
University of Utah - Huntsman Cancer Institute (USA)	16	20	6	2	8c	0	7	9	1	3	0	14	2	0	0	0	0
Walter and Eliza Hall Institute of Medical Research (WEHI) (AU)	59	62	19i	6	34j	0	58	0	0	1	0	0	0	0	0	0	59
Washington University (USA)	68	73	27	4	37	0	33	0	0	40	0	50	0	18	0	0	0
TOTAL	506	537	181	39	281	5	401	28	13	75	3	154	29	50	9	5	259
PERCENT OF TOTAL			36	8	56	1						30	6	10	2	1	51

^a(2 BRCA1; 1 BRCA2)

^b(4 BRCA1)

^c(1 BRCA2)

^d(1 BRCA1, 1 metaplastic, 2 metaplastic mixed ductal)

^eMedullary

^f5 BRCA1, 4 BRCA2, 4 metaplastic

^gDefined as "Stable" at passage 2

^hAll treatment naïve

ⁱ(4 BRCA1; 1 BRCA2)

^j(1 BRCA2)

^k(8 BRCA1; 1 BRCA2; 2 metaplastic)